Abstract
Despite the significant advances in the medical research and treatment methods, the rate of mortality associated with cardiovascular disease (CVD) is continuously rising and it remains the leading cause of death worldwide. There are several treatment methods for CVD and associated complications that have been considered till now. The current treatment methods cannot produce rapid cure, but could prevent or reduce the progression of this devastating disease. In the current article, we have summarized the use of various pharmacological agents viz. HMG-CoA reductase inhibitors (statins), antihypertensive, thrombolytic and anticoagulation agents that are currently being used for the management of CVD which targets different biochemical or molecular events. Based on our article, more research in this field is advocated which will provide the rapid and effective treatment methods in order to avoid fatal complications associated with CVD.
Keywords: Anticoagulation agents, antihypertensive agents, antithrombolytic agents, Statins.
Current Pharmaceutical Design
Title:Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Volume: 22 Issue: 5
Author(s): Nasimudeen R. Jabir, Ali Nasir Siddiqui, Chelapram Kandy Firoz, Ghulam Md Ashraf, Syed Kashif Zaidi, Mohd Shahnawaz Khan, Shazi Shakil, Mohammed Nabil Alama, Mohammad Amjad Kamal and Shams Tabrez
Affiliation:
Keywords: Anticoagulation agents, antihypertensive agents, antithrombolytic agents, Statins.
Abstract: Despite the significant advances in the medical research and treatment methods, the rate of mortality associated with cardiovascular disease (CVD) is continuously rising and it remains the leading cause of death worldwide. There are several treatment methods for CVD and associated complications that have been considered till now. The current treatment methods cannot produce rapid cure, but could prevent or reduce the progression of this devastating disease. In the current article, we have summarized the use of various pharmacological agents viz. HMG-CoA reductase inhibitors (statins), antihypertensive, thrombolytic and anticoagulation agents that are currently being used for the management of CVD which targets different biochemical or molecular events. Based on our article, more research in this field is advocated which will provide the rapid and effective treatment methods in order to avoid fatal complications associated with CVD.
Export Options
About this article
Cite this article as:
Jabir R. Nasimudeen, Siddiqui Nasir Ali, Firoz Kandy Chelapram, Ashraf Md Ghulam, Zaidi Kashif Syed, Khan Shahnawaz Mohd, Shakil Shazi, Alama Nabil Mohammed, Kamal Amjad Mohammad and Tabrez Shams, Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases, Current Pharmaceutical Design 2016; 22 (5) . https://dx.doi.org/10.2174/1381612822666151125000746
DOI https://dx.doi.org/10.2174/1381612822666151125000746 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Glycation End Products and Insulin Resistance
Current Pharmaceutical Design Estriol Inhibits Dermcidin Isoform-2 Induced Inflammatory Cytokine Expression Via Nitric Oxide Synthesis in Human Neutrophil
Current Molecular Medicine MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Current Pharmaceutical Design Sleep Disorders Research From 1945 to 2020: A Bibliometric Analysis
CNS & Neurological Disorders - Drug Targets Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine Melatonin in Cardiac Ischemia/Reperfusion-Induced Mitochondrial Adaptive Changes
Cardiovascular & Hematological Disorders-Drug Targets Editorial from Guest Editor [Hot Topic:Vitamin D and Respiratory Health (Guest Editor: Adrian R. Martineau)]
Current Respiratory Medicine Reviews Metabolic Programming Nowadays (or Perhaps Now and then?)
Current Nutrition & Food Science Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation
Current Cardiology Reviews Novel C-9, 9'-O-acyl Esters of (-)-Carinol as Free-radical Scavengers and Xanthine Oxidase Enzyme Inhibitors: Synthesis and Biological Evaluation
Medicinal Chemistry Inhibitory Effects of Some Bryophytes on Glutathione-S -Transferase
Current Enzyme Inhibition The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology